Balyasny Asset Management
SCLN

Balyasny Asset Management’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Balyasny Asset Management’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-30,800
Closed -$345K – 2525
2017
Q3 		$345K Buy
+30,800
New +$340K ﹤0.01% 1477
2017
Q2 		– Sell
-17,575
Closed -$172K – 1935
2017
Q1 		$172K Sell
17,575
-1,130
-6% -$11.3K ﹤0.01% 1495
2016
Q4 		$202K Buy
18,705
+2,630
+16% +$26.3K ﹤0.01% 1285
2016
Q3 		$165K Buy
16,075
+4,900
+44% +$53.4K ﹤0.01% 894
2016
Q2 		$146K Sell
11,175
-5,210
-32% -$68.3K ﹤0.01% 1070
2016
Q1 		$180K Buy
+16,385
New +$146K ﹤0.01% 1144

Balyasny Asset Management's SCLN Position: Q4 2017 in Review

Balyasny Asset Management sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2017, closing a stake of 30,800 shares — an estimated $345K sold.

Balyasny Asset Management first reported a position in SCLN in Q1 2016 and held it in 6 quarters. The position peaked at $345K in Q3 2017. 0 funds tracked by Wall St. Rank hold SCLN as of Q4 2017.

  • Balyasny Asset Management reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
  • Balyasny Asset Management sold 30,800 Sciclone Pharmaceuticals Inc shares in Q4 2017, an estimated $345K.
  • Balyasny Asset Management first reported a position in Sciclone Pharmaceuticals Inc in Q1 2016 and held it in 6 quarters.
  • Balyasny Asset Management's Sciclone Pharmaceuticals Inc position peaked at $345K in Q3 2017.
  • 0 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2017.

Based on Balyasny Asset Management's 13F filing for Q4 2017, filed 14 Feb 2018.